gilead yeztugo - Search News

News

HIV, Gilead Sciences and FDA

Moneyweb · 33m

Gilead’s twice-a-year HIV prevention shot wins FDA approval

Gilead Sciences said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people.

Barron's on MSN · 8h

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

Yahoo Finance · 10h

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg,

11mon MSN

The world's only twice-a-year shot to prevent HIV could stop transmission -- if people can get it

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated ...

Fierce Pharma10h

FDA signs off on Gilead’s landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results